Form 4 Tracker
Jean Jacques Bienaime

Director · 13 filings · Latest: Jun 15, 2026

Ascendis Pharma A/S
Immunome Inc.
INCYTE CORP
Keros Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
KROS
Jean Jacques BienaimeDirectorJun 15, 2026
Purchase
$10.191,000$10.2K17,592
IMNM
Jean Jacques BienaimeDirectorJun 5, 2026
Purchase
$19.4510,500$204.3K43,415
IMNM
Jean Jacques BienaimeDirectorJun 5, 2026
Sale
$19.4110,500$203.8K32,915
ASND
Jean Jacques BienaimeDirectorMay 29, 2026
Purchase
$223.12500$111.6K900
INCY
Jean Jacques BienaimeDirectorMay 26, 2026
Option Exercise
$84.5315,000$1.3M35,841
ASND
Jean Jacques BienaimeDirectorMay 26, 2026
Purchase
$237.80400$95.1K400
KROS
Jean Jacques BienaimeDirectorMay 15, 2026
Purchase
$10.581,000$10.6K9,450
IMNM
Jean Jacques BienaimeDirectorMay 15, 2026
Purchase
$20.705,000$103.5K43,415
KROS
Jean Jacques BienaimeDirectorApr 15, 2026
Purchase
$11.701,000$11.7K8,450
IMNM
Jean Jacques BienaimeDirectorMar 11, 2026
Purchase
$21.551,000$21.6K38,415
IMNM
Jean Jacques BienaimeDirectorMar 10, 2026
Purchase
$22.121,000$22.1K37,415
KROS
Jean Jacques BienaimeDirectorMar 9, 2026
Purchase
$11.212,000$22.4K7,450